Mikhail Ya. Kissin

Mikhail Ya. Kissin

Auto-generated profile, based on publicly available information

Mikhail Ya. Kissin

Pavlov First St. Petersburg State Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2025 in Epilepsy and paroxysmal conditions
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Violetta V GrechkinaVioletta V Grechkina
Violetta V Grechkina
MKM. Ya. Kissin
M. Ya. Kissin
ДDДиана Викторовна Dmitrenko
Диана Викторовна Dmitrenko
RNRegina F. Nasyrova
Regina F. Nasyrova
Background. Eating behaviour disorder (EBD) induced by valproic acid (VPA) is one of the components of the pathogenesis of a serious complication of therapy with VPA and its salts such as VPA-induced metabolic syndrome (MetS). About 20% of patients receiving VPA have weight gain, which is also a consequence of altered eating behaviour in such patients. Substances such as neuropeptide Y (NPY), leptin, orexin and ghrelin are involved in the regulation of eating behaviour. NPY has received special attention in recent years because it is one of the most potent brain orexigenic peptides and its expression level directly affects the quantity and quality of food intake. NPY overexpression is associated with EBD, food preferences, obesity, and MetS.Objective: to review preclinical and clinical studies of NPY role as a potential sensitive and specific serum biomarker of VPA-EBD, secondary weight gain and VPA-MetS development in children and adults with epilepsy.Material and methods. We analyzed Russian and foreign publications submitted to eLibrary, PubMed/MEDLINE, Scopus, and Google Scholar databases between 2014 and 2024. The full-text articles in Russian and English (original studies, systematic reviews, meta-analyses, Cochrane reviews, and clinical cases) were analyzed. After the selection procedure, 53 out of 1105 publications retrieved by query keywords were included in the analysis.Results. VPA-EDB refers to multifactorial diseases, requiring to take into account the additive contribution of external (food education, eating habits of the patient and family members) and internal (key hormones and neuropeptides regulating appetite and food preferences, the dose and duration of VPA intake, the metabolic rate of VPA) factors while assessing a risk of its development. NPY-associated VPA-EDB affects dietary preferences in favor of high-calorie food and beverages, increases the frequency of meals, the risks of insulin resistance, hyperglycemia as one of the major domains in MetS pathogenesis.Conclusion. VPA-EBD requires timely diagnosis, as it can cause VPA-MetS. NPY is an important biomarker of VPA-EBD, because recent studies have convincingly demonstrated that this neuropeptide is involved in the regulation of eating behavior in patients with epilepsy.

8 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Violetta V GrechkinaVioletta V Grechkina
Violetta V Grechkina
VTVera Trefilova
Vera Trefilova
MKMikhail Ya. Kissin
Mikhail Ya. Kissin
Ekaterina Andreevna NarodovaEkaterina Andreevna Narodova
Ekaterina Andreevna Narodova
RNRegina F. Nasyrova
Regina F. Nasyrova
The safety of the use of psychotropic drugs, widely used in neurological and psychiatric practice, is an urgent problem in personalized medicine. This narrative review demonstrated the variability in allelic frequencies of low-functioning and non-functional single nucleotide variants in genes encoding key isoenzymes of valproic acid P-oxidation in the liver across different ethnic/racial groups. The sensitivity and specificity of pharmacogenetic testing panels for predicting the rate of metabolism of valproic acid by P-oxidation can be increased by prioritizing the inclusion of the most common risk allele characteristic of a particular population (country).

2 November 2023 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
Verified
Journal Article
Open access
PDF file
YYY. A. Yakovleva
Y. A. Yakovleva
MKM. Y. Kissin
M. Y. Kissin
EGE. V. Gumennik
E. V. Gumennik
SSS. V. Semenova
S. V. Semenova
ЮЯЮ. А. Яковлева
Ю. А. Яковлева
The clinical and anamnestic method analyzed 496 outpatient records of children and adolescents suffering from epilepsy in order to identify data contributing to the development and influencing the nature and severity of comorbid mental disorder. The presence of cognitive and affective disorders of varying severity was noted in 415 (83.6%) patients. As an addition to the neurological diagnosis was revealed: 171 patients (61.3%) had anxiety-depressive syndrome, 245 patients (87.8%) had emotional-volitional instability syndrome, and 101 patients (36.2%) had autism spectrum disorder (ASD). But further psychiatric verification of these syndromes in accordance with ICD-10 was not carried out. Clinical, neurophysiological and morphological characteristics of comorbid mental symptoms in epilepsy in childhood and adolescence were revealed.

30 December 2021 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
Verified
Journal Article
Open access
PDF file
YYY. A. Yakovleva
Y. A. Yakovleva
MKM. Y. Kissin
M. Y. Kissin
YPY. V. Popov
Y. V. Popov
APA. A. Pichikov
A. A. Pichikov
NSN. Y. Safonova
N. Y. Safonova
TGT. M. Goguadze
T. M. Goguadze
Introduction: psychosis in epilepsy is more common than in the general population. The frequency of psychotic mental disorders varies from 0,5% to 10%. The article presents the dynamics of the development of the concept of epileptic psychosis, depending on the evolutionary approaches to the study of the problem of mental disorders in epilepsy. Materials and methods: the analysis of Russian—and English language articles in scientific databases on keywords from 1971 to 2011 was carried out. Results: the first systematic descriptions of mental disorders occurring in epilepsy date back to the 19th century. The contribution of foreign and domestic authors to the study of the problem is described. There are six main periods of the concept formation, including the definitions of the concept of epileptic psychosis, the dynamics of clinical manifestations, the role of the influence of biological, personal and social factors in the genesis and development of psychotic disorders in epilepsy. The following risk factors for the development of psychosis are considered: the form of epilepsy; age of onset of seizures, lateralization of the epileptic focus, gender, and drug therapy. Variants of classification approaches to the problem are presented. The article discusses the differences in the systematization of «endoform» syndromes, as well as the parallels between schizophrenia and psychoses in epilepsy. The dynamics of scientific views on the interest in the formation of epileptic psychoses in various parts of the brain: the temporal lobe (amygdala, hippocampus, paralimbic zones and parahippocampal bend), as well as GABA-ergic neurons of the upper tubercles of the quadriplegic, posterior hypothalamus and serotonergic neurons of the dorsal suture and noradrenergic neurons of the blue spot are reflected. The association of psychopathological manifestations with neurophysiological, biochemical, genetic and morphofunctional correlates is noted. The authors‘ interest in psychoses associated with the use of antiepileptic drugs is emphasized. Conclusion: despite all attempts to systematize these conditions, the factors that provoke the development of psychoses in patients with epilepsy, their structure and prognosis remain poorly predictable and require further in-depth study.

30 June 2025 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Violetta V GrechkinaVioletta V Grechkina
Violetta V Grechkina
MKM. Y. Kissin
M. Y. Kissin
RNRegina F. Nasyrova
Regina F. Nasyrova
Вальпроат-индуцированные нарушения метаболизма дофамина и развитие вальпроат-индуцированного паркинсонизма: новый взгляд на профилактику и диагностику

31 March 2026 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Violetta V GrechkinaVioletta V Grechkina
Violetta V Grechkina
RNRegina F. Nasyrova
Regina F. Nasyrova
MKM. Ya. Kissin
M. Ya. Kissin
INTRODUCTION. Lamotrigine (LTG) is among the most commonly prescribed second-generation antiepileptic drugs due to its low teratogenic risk. However, lamotrigine has pronounced neurotoxic, hepatotoxic, dermatotoxic potential (for genetic and metabolic causes) and in some cases can even cause multi-organ failure. Understanding lamotrigine mechanism can help individualise therapy and increase its safety, considering pharmacodynamics and pharmacometabolomics that determine its metabolism, transport, and elimination in a particular patient. AIM. This study aimed to develop an approach to lamotrigine therapy of epilepsy and other neurological and psychiatric diseases reducing neurotoxicity, with due regard to pharmacogenomics and pharmacometabolomics. RESULTS. LTG is metabolised in the liver in two pathways: glucuronidation (major pathway) and P-oxidation (minor pathway). As a result, neutral and toxic (reactive) lamotrigine metabolites are produced that can circulate in blood serum for a long time, penetrate the damaged blood-brain barrier in patients with therapy-resistant seizures and have a neurotoxic effect, triggering or maintaining neurotransmission disorders, impaired synaptic plasticity, neuronal apoptosis and other neurodegeneration mechanisms. An important role in lamotrigine neurotoxicity belongs to transport proteins involved in the efflux (excretion) of reactive (toxic) metabolites from the brain into the systemic circulation, as well as from hepatocytes into the gastrointestinal tract by bile and through the kidneys with urine. Genetically determined delayed efflux through the blood-brain barrier (pharmacogenomics) increases lamotrigine neurotoxic potential. CONCLUSION. To assess the risk of lamotrigine-induced adverse reactions, together with clinically assessing patient’s condition, it is recommended to: 1) monitor drug distribution (blood, hair, saliva, breast milk); 2) analyse potentially toxic metabolites (blood, saliva, hair); 3) perform pharmacogenetic tests for non-functional polymorphisms of genes encoding key transport proteins and enzymes involved in drug metabolism. Results of pharmacogenetic and pharmacometabolic tests applied in the clinical practice of an epileptologist will allow to manage lamotrigine neurotoxiсity.